latest news releases from the newsroom
Dobson Communications Corporation
Dobson Communications Approved for Trading on Nasdaq National Market
OKLAHOMA CITY, Nov. 19, 2003 (PRIMEZONE) -- Dobson Communications Corporation (Nasdaq:DCEL) today announced that its Class A common stock has been approved for trading on the Nasdaq National Market. The Company expects the move from the Nasdaq SmallCap to the Nasdaq National Market will be effective at the open of regular trading today. Dobson's Class A common stock will continue to trade under the symbol DCEL.
Duke University Study Abstract Shows Significantly Lower Incidence of Major Adverse Cardiac Events Following Percutaneous Coronary Intervention Using Visipaque Compared to Isovue
BUCKINGHAMSHIRE, U.K., Nov. 19, 2003 (PRIMEZONE) -- The findings of a Duke University study abstract that were reported at the American Heart Association meeting November 9-12 in Orlando, Florida, indicated that the use of Visipaque(TM) (iodixanol), a diagnostic pharmaceutical produced by Amersham plc (LSEAHM) (NYSE:AHM) (OSE:AHM), was found to have a significantly lower incidence of in-hospital major adverse cardiac events (MACE) compared to Isovue(R) (iopamidol) in patients who undergo an interventional therapeutic cardiac procedure.Visipaque(TM) is a nonionic, isosmolar contrast medium used to provide enhanced X-ray images of soft tissues, primarily blood vessels and organs, for the diagnosis of many common diseases.
Calypso Wireless, Inc.
Calypso Wireless and Nocable Sign a Field Trial Agreement
MIAMI LAKES, Fla., Nov. 19, 2003 (PRIMEZONE) -- Calypso Wireless Inc. (Pink Sheets:CLYW) announced today it has signed a field trial installation agreement with Nocable SpA. an Italian-based regional telecommunications company. Calypso Wireless will conduct the field trial on Nocable's Wi-Fi network, WIND Telecomunicazioni SpA. and Telecom Italia Group (NYSE:TI) GSM/GPRS mobile networks, which are the leading mobile operators in Italy.
Industrivarden evaluating a sale of Isaberg Rapid
STOCKHOLM, Sweden, Nov. 19, 2003 (PRIMEZONE) -- Industrivarden has the intention to sell its wholly owned subsidiary Isaberg Rapid. A process has been initiated with the aim of finding a new owner that will continue the successful development of the company.
Celltech Group plc
Celltech Announces Completion of OGS Integration Process
SLOUGH, UK, Nov. 19, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announced today that it has completed its integration of Oxford GlycoSciences (OGS), which was acquired in May 2003. This acquisition has provided Celltech with substantial assets, including six novel oncology research programmes supported by around 40 high quality scientists, a royalty stream from the marketed product Zavesca(R), and a Phase I development programme, CDP 923, for the treatment of certain inherited storage disorders. The acquisition has met Celltech's goal of being both cash and earnings neutral.
Anoto Functionality Powers New HP Forms Automation System
LUND, Sweden, Nov. 19, 2003 (PRIMEZONE) -- Yesterday, during Comdex in Las Vegas, HP launched HP Forms Automation System (HP FAS), a solution enabled by Anoto technology. HP's new solution will significantly improve forms based business processes for medium and large enterprises. The HP FAS will be available in North America and Western Europe in November 2003.
Celltech Group plc
Celltech Group plc -- Closure of Seattle Research Facility
SLOUGH, U.K., Nov. 19, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announced today a reorganisation of its R&D operations designed to rebalance resources between its research and development activities. It will close its novel target discovery facility in Seattle, US at the beginning of 2004, with certain key activities being transferred to other sites. The annualised savings deriving from this closure of approximately GBP11.5 million will be reinvested in R&D, with particular focus on accelerating Celltech's early stage development pipeline, including novel anti-inflammatory treatments CDP 484, CDP 323 and CDP 146.